Previously, little is known about the relationship between the PIK3R1
mutation status and the resistance to HER2-targeted therapies. Herein,
we report a HER2-positive breast cancer patient with PIK3R1EY451delinsD
showed resistance to HER2-targeted therapy, and adding everolimus to the
treatment of trastuzumab and carboplatin achieved better effect.